Blueprint Medicines

Yahoo Finance • 8 months ago

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

CAMBRIDGE, Mass., April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024... Full story

Yahoo Finance • 9 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 10 months ago

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU... Full story

Yahoo Finance • 10 months ago

Blueprint Medicines Full Year 2023 Earnings: Beats Expectations

Blueprint Medicines (NASDAQ:BPMC) Full Year 2023 Results Key Financial Results Revenue: US$249.4m (up 22% from FY 2022). Net loss: US$507.0m (loss narrowed by 9.1% from FY 2022). US$8.37 loss per share (improved from US$9.35 loss in FY 2... Full story

Yahoo Finance • 12 months ago

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified sto... Full story

Yahoo Finance • last year

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan H... Full story

Yahoo Finance • last year

Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (NASDAQ:BPMC) has recently witnessed a notable insider sell by Director Jeffrey Albers, who disposed of 5,000 shares of the company's stock. The transaction took place on December 11, 2023, and has caught the atten... Full story

Yahoo Finance • last year

Blueprint Medicines' (NASDAQ:BPMC) investors will be pleased with their respectable 63% return over the last year

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Blueprint Medicines Corporation (NASDAQ:BPMC) share price is up 63% in the... Full story

Yahoo Finance • last year

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • 2 years ago

FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study

The FDA lifted the partial clinical hold on Blueprint Medicines Corporation's (NASDAQ: BPMC) Phase 1/2 VELA trial of BLU-222. In February, the agency placed a partial clinical hold on the VELA trial due to reported visual adverse events, c... Full story

Yahoo Finance • 2 years ago

Ken Fisher Super Stocks: 10 Biggest Small-Cap Stocks

In this article, we discuss the 10 biggest small-cap stocks in the Ken Fisher portfolio. If you want to see more stocks in this selection, check out Ken Fisher Super Stocks: 5 Biggest Small-Cap Stocks. US stocks have been beaten down by i... Full story

Yahoo Finance • 2 years ago

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulti... Full story

Yahoo Finance • 2 years ago

Blueprint's stock falls 11% after sharing new Phase 2 data for its rare-disease therapy

Shares of Blueprint Medicines Corp. tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic mastocytosis, a rare disorder, met the primary and... Full story

Yahoo Finance • 2 years ago

IDRx Emerges From Stealth With $122M To Tackle Cancer

Massachusetts-based IDRx emerged from stealth on Tuesday armed with $122 million in Series A funding to bring combination therapies to the forefront of cancer treatment. The oversubscribed round was co-led by Andreessen Horowitz and life s... Full story

Yahoo Finance • 2 years ago

Top 10 Stock Picks of Eli Casdin’s Casdin Capital

In this article, we discuss the top 10 stock picks of Eli Casdin's Casdin Capital. If you want to skip our detailed analysis of Casdin's investment philosophy and performance, go directly to Top 5 Stock Picks of Eli Casdin's Casdin Capital... Full story

Yahoo Finance • 2 years ago

Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion

Shares of Blueprint Medicines Corp. gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma , which acquires pharmaceutical royalties, worth up to $1.2 billion. S... Full story

Yahoo Finance • 2 years ago

Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million

Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Royalty... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or the “Company”) (NASDAQ: BPMC).   Such investors are advised to contact Robert S.... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation - BPMC

NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation (“Blueprint” or the “Company”) (NASDAQ: BPMC).   Such investors are advised to contact Robert S.... Full story

Yahoo Finance • 3 years ago

10 Stocks Making Headlines Today

In this article, we will discuss some of the notable stocks trending today. To take a look at some more stocks that are in the news, go to 5 Stocks Making Headlines Today. US equity market is in the red on Wednesday despite stronger-than-... Full story